Hipertensión intracraneal benigna como efecto secundario del tratamiento con hormona de crecimiento biosintética

Anales Espanoles de Pediatria

Volumn 44, Issue 5, 1996, Pages 507-508

  De la Vega, J A Bermúdez ^a,c   Martinez Martinez J J ^a   Fernandez Fiscer P ^b   Gonzalez Hachero J ^a  

^a Servicio de Pediatria Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; LEVOTHYROXINE; GROWTH HORMONE; THYROXINE;

ARTICLE; CASE REPORT; HUMAN; HYPOTHYROIDISM; INTRACRANIAL HYPERTENSION; MALE; SCHOOL CHILD; BRAIN PSEUDOTUMOR; CHEMICALLY INDUCED DISORDER; CHILD; DRUG COMBINATION; HYPOPITUITARISM; REVIEW;

CHILD; DRUG THERAPY, COMBINATION; GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; PSEUDOTUMOR CEREBRI; THYROXINE;

EID: 0029953282     PISSN: 03024342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Wilton P. Adverse Events During Growth Hormone Treatment: 5 Years' Experience in the Kabi International Growth Study. Ranke MB, Gunnarson R (eds). Progress in Growth Hormone Therapy -5 Years of KIGGS J and J Verlag Manheim, 1994; págs. 291-307.
2. Hernández M. Criterios actuales del tratamiento con hormona de crecimiento. Rev Esp Pediatr 1990;46.1-16.
3. Watanabe S, Mizuno S, Oshima LH, Tsunematsu Y, Fujimoto J, Komiyana A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol 1993;6:99-108.
4. Ogilvy-Stuart AL, Ryder WD, Gattmaneni HR, Clayton PE, Shalet SM. Growth hormone and tumor recurrence. BMJ 1992;304:1601-1605.
5. Costin G, Kogut MD. Carbohydrate tolerance in gonadal dysgenesis: Evidence for insulin resistance and hyperglucagonemia. Horm Res 1985;22:260-269.
6. Malozowski S, Tanner LA, Wysowski D, Fleming GA Growth hormone, insulin-like growth factor I and benign intracranial hypertension N Engl J Med 1993;329:665-666.